Tiny worms found in ponds and river could help treat schizophrenia
The worms come from a family known as planaria, with some species previously thought to be "immortal" due to their unique regenerative abilities, which includes the ability to regenerate lost body parts, including entire brains.
A team of scientists at the University of Reading gave the worms haloperidol, a drug used to treat mental health conditions, and found the worms became much less active, just like mice and rats do.
Previous studies have used planaria to research epilepsy treatments and to investigate drug addiction, as the flatworms exhibit signs of withdrawal symptoms. This new study could help to develop treatments for mental health conditions such as schizophrenia and hallucinations.
A 2024 study reported that one in 69 UK adults are using anti-psychotic medication long-term.
Professor Vitaliy Khutoryanskiy, who led the study from the University of Reading, said: "This finding adds to growing evidence that tiny flatworms like planaria could play a valuable role in how we study the brain. They display certain responses to psychiatric drugs that resemble those seen in mammals, but using them involves far fewer ethical concerns."
According to UK government data, 882,000 mice and 144,060 rats were used in animal research in 2023. A 2016 study suggested the use of rats and mice in neuroscience had risen from 20 per cent in the 1980s, to over 50 per cent by the 2010s.
Despite efforts to make research more ethical, scientists still rely heavily on rodents for testing. The researchers said using flatworms for studying brain conditions could potentially reduce the number of rodents used by scientists.
Professor Khutoryanskiy added: "Close to a million mice and rats are used in UK research each year, but using planaria instead could potentially cut those numbers and still give us the answers we need to develop better treatments for people with serious mental health conditions. It's good for science and it's good for animal welfare."
The research is published in the journal Pharmaceutical Research.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
3 simple ways to spot fake weight loss jabs after Mounjaro price hike
With the price of Mounjaro set to almost triple in the UK, there are fears more and more people will turn to counterfeits. A former Big Brother star has said she "thought she was going to die" after taking a "fake" weight loss jab amid fears of a spike in black market demand as the price of Mounjaro is due to almost triple in the UK. Aisleyne Horgan Wallace told Good Morning Britain she suffered an adverse reaction when she bought the jab online. She said she temporarily lost her sight in one eye, suffered extreme vomiting and was in excruciating pain from the jab. Wallace said she took several doses before one left her bedridden and in and out of consciousness for several days. She has now warned about the dangers of counterfeit jabs after admitting it was a "foolish thing to do." Their high cost and limited availability have led to a flourishing black market for fake jabs. The National Pharmacy Association has warned about the risk of buying the jabs online without consulting a medical professional. In May, ITV News analysed some fake jabs they acquired at a "skinny jab party" and found they contained none of the active ingredients that contribute to weight loss. But there are fears that black market problems will get worse before they get better as Mounjaro's producer, Eli Lilly, is set to increase prices in the UK. Eli Lilly has said it will increase its prices in the UK from September after Donald Trump ramped up pressure on US pharmaceutical companies. The US president has promised to stop the disparity between what Americans pay for US-produced drugs compared to other countries, which often pay far less. The Rand Corporation think tank has said that US consumers pay three times more for drugs than in other developed countries. Trump has urged companies to close the gap and has threatened reprisals for those who do not do it voluntarily. There are fears that, rather than lowering the US price, drug companies will just raise their global price to meet Trump's demands, as appears to be the case with Eli Lilly. How much is Mounjaro increasing? Eli Lilly has said it will increase the price of the drug from September by 170%. A month's supply of the highest dose is rising from £122 to £330. Eli Lilly said the NHS would not pay for a higher price, so it will still be prescribed for people with obesity and type 2 diabetes. It will be the people who buy the jab privately through pharmacies or online stores that pay the higher price. The company has said private healthcare providers will be able to negotiate their own prices for purchasing the drug. Mounjaro is seen as the best weight-loss drug available by some, although Wegovy, made by Danish company Novodisk, has seen a huge surge in demand as a result of the price rises. A trial comparing the drugs found that people who took Mounjaro over 72 weeks lost 22.8kg compared to 15kg for people who took Wegovy. This has all led to a surge in people being uncompromising in their desire for Mounjaro and has led to many looking for alternative ways to secure their jabs. Medical professionals warn about people turning to counterfeits The price increase has led to people purchasing as many Mounjaro jabs as possible, but medical professionals have warned to be careful where you buy them from. Professor Claire Anderson, president of the Royal Pharmacist Society (RPS), told the Independent: "Counterfeit medicines from unregulated sources pose serious health risks - they can contain incorrect doses, harmful substances or no active ingredient at all." Jason Murphy, Head of Pharmacy at online retailer Chemist4U, said: "With the recent price hikes, we're likely to see more and more people turning to unregulated sellers because the medication may be cheaper. "This is extremely unsafe as many of these sources distribute counterfeit versions of Mounjaro, which pose serious risks to your health." The National Pharmacy Association has urged the government to improve regulation around online purchase of weight loss jabs to ensure people get the proper medical advice when buying them. How to spot fake weight loss jabs Chemist4U said there were three main identifiers to suggest a jab is fake. First, cost is a big one, the price of these jabs is set at certain points, with most retailers selling them at only a small profit. If you see one for considerably cheaper than normal, ask yourself how the seller got this from the manufacturer cheaper than large high street chains did. Secondly, currently in the UK Wegovy and Mounjaro are prescription-only medicines and can only be issued after a consultation. You can buy them from stores like Boots or Asda Pharmacy, but they will require a medical consultation first. If a vendor is selling them without this step, then you should steer clear of buying them. Finally, they will also look different. Chemist4U says "the materials used for real pens feel solid and well made, whereas a fake pen is likely to feel cheap, flimsy and have more obvious flaws like uneven colouring, rough edges or loose parts". They also point out that the real pens each have a unique serial number, whereas fake ones will not have one or a fake one.
Gizmodo
13 minutes ago
- Gizmodo
Ozempic Maker Novo Nordisk Freezes Hiring Amid Ongoing Struggles
No one stays on top forever. It's a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish pharmaceutical company has enacted a hiring freeze—the latest sign of a sinking financial outlook for the once-titan of the obesity treatment world. Reuters reported on the hiring freeze Wednesday. The company has faced numerous setbacks in recent months, including billions shaved off its stock market value and continued competition from cheaper, compounded versions of its blockbuster drug semaglutide. Though the freeze will apparently only apply to certain segments of the company, layoffs are likely not far off in the distance. 'We currently have a hiring freeze in non-business critical areas,' said Novo Nordisk in a statement to Reuters. Semaglutide is the active ingredient in Novo Nordisk's diabetes drug Ozempic and obesity medication Wegovy. It and similar compounds mimic the hormone GLP-1, which helps regulate insulin production and our appetite (among other functions). Though GLP-1 drugs have existed for two decades, semaglutide has proven more effective at helping people lose weight than diet and exercise alone, as well as other older medications. The approval of Wegovy in 2021 greatly reshaped the field of obesity medicine and earned plenty of money for Novo Nordisk. In 2024, the company reported about $42 billion dollars of revenue, driven by increasing sales of Wegovy and Ozempic (sometimes prescribed off-label for weight loss treatment). The company's success was so tremendous that it even helped bolster Denmark's local economy. But the company's meteoric rise has stumbled as of late for several reasons. For starters, it's no longer the only game in town, following the approval of Eli Lilly's tirzepatide for obesity (under the name Zepbound) in 2023. The drug, which combines GLP-1 with another weight-related hormone, is generally more effective than semaglutide, and people have steadily started to prefer it. Though Ozempic and Wegovy might still be more well known to the public, prescriptions of Zepbound in the U.S. now appear to be surpassing the former. Ozempic-Maker CEO Ousted Over Pharma Company's Rocky Market Downturn Novo Nordisk has also explicitly cited the emergence of the compounded drug market for GLP-1 therapy for its recent struggles. Compounded drugs are custom-made formulations of semaglutide and tirzepatide, often much cheaper, and produced by specialized pharmacies. The Food and Drug Administration has attempted to crack down on this industry, but many companies are still producing these drugs, and many people are still buying them. The fight over these compounded drugs has become so fierce that Novo Nordisk abruptly ended its newly formed partnership with telehealth company Hims in June. The company alleged that Hims was trying to deceptively market their compounded version of semaglutide over Wegovy to its users (Hims, for its part, has denied the accusation). These headwinds led Novo Nordisk to admit earlier this year that its projected sales growth in 2025 will fall short of past projections, which has since fueled further financial calamity. In May, the company fired its longtime CEO amid declining stocks. In July, investors wiped off $70 billion from the company's market value after it once again lowered its sales growth forecast for the remainder of the year. Sales of Wegovy and Ozempic do remain strong overall. And Novo Nordisk is developing other treatments intended to reclaim its throne in the obesity medicine field (including weight loss pills and drugs potentially more effective than any other treatment to date). But the company's fortunes are likely to worsen before they get better. Novo Nordisk Abruptly Ends Partnership with Hims, Claiming 'Sham Compounding' GLP-1 Drugs Departing CEO Lars Fruergaard Jørgensen stated in early August that the company, which currently employs nearly 80,000 people, will probably experience layoffs. The company's new CEO, Maziar Mike Doustdar, is also considering layoffs, according to a recent report from Danish TV2. This new era of obesity treatment isn't going anywhere anytime soon. But whether Novo Nordisk will remain the big dog on top is much more in question today than it would have been even just a few months ago.
Associated Press
14 minutes ago
- Associated Press
Bones of ancient child suggest humans could have interbred with Neanderthals earlier than thought
TEL AVIV, Israel (AP) — Modern humans and Neanderthals were interacting 100,000 years earlier than previously thought, according to researchers who used CT scans and 3D mapping to study the bones of a child they believe was the result of interbreeding between the two distinct groups. The child, described in a recent study published in the peer-reviewed journal L'Anthropologie, was buried in a cave in Israel some 140,000 years ago. Because no ancient DNA was extracted from the fossilized remains, it's impossible to confirm the child's origins, but scientists say microscopic details in the bones indicate the child had traits of both groups. When the bones were first excavated from Skhul Cave in northern Israel in 1931, archaeologists recognized that the child belonged to neither Homo sapiens, who had arrived in the region from Africa, nor Neanderthals, who arrived from Europe. They concluded it was a separate species indigenous to the area. But the new 3D mapping allowed researchers to study small details of the skull that had previously been difficult to see or decipher. Researchers were able to examine distinctive traits such as the construction of the inner ear and the imprint of blood vessels that supplied the brain. By comparing known characteristics of both Homo sapiens and Neanderthals, the researchers concluded the child was the result of interbreeding. Previously, the earliest known example of interbreeding between the groups was around 40,000 years ago in central Europe, explained Israel Hershkovitz, the lead researcher of the study and a professor of archaeology and human evolution at Tel Aviv University. A new glimpse into ancient relations The new research helps shed light on when the two groups began interacting and offers clues about their relationships. 'What we're saying now is that there was an extensive relationship between Homo sapiens and Neanderthals that started around 140,000 years ago,' and the two groups 'managed to live side by side with no evidence for hostile encounters,' Hershkovitz said. The interbreeding and shared cultural practices, including burials and tool construction, challenge the notion of Homo sapiens as 'intolerant' to other human groups due to their eventual dominance, Hershkovitz said. Without DNA, it will be impossible to prove that the child was a hybrid human, said Pascal Gagneux, an evolutionary biologist studying human origins at the University of California San Diego who was not involved in the research. Still, he said, the details revealed by the mapping, including the internal structure of some bones and several features, support the hybrid hypothesis. Peering inside an ancient skull Researchers took thousands of isolated scans of the skull and jaw of the child and then created a virtual 3D model of the fossil. The model allowed them to analyze tiny details that are impossible to see on the fossilized bones, including delicate parts inside the skull. Blood vessels, for example, make a small imprint on the inside of a skull. While some of the grooves are visible to the naked eye, the 3D scans allowed researchers to see the blood vessels like 'tributaries of a river,' Hershkovitz said. The patterns are distinct between the two groups, because Neanderthals and Homo sapiens have different brain shapes that require different blood delivery. The virtual mapping created a more accurate reconstruction of the child's skull than could be built from the bones and plaster when the remains were originally excavated. The new reconstruction is much more elongated, which is more typical for Neanderthals, Gagneux said. However, the detailed reconstruction does not answer many of the questions surrounding the discovery, Gagneux said. Were the parents of the child also interbred? Or was one Neanderthal and the other Homo sapien? Why was the child, or anyone else, buried in the cave? Thomas Levy, a professor in cyber-archaeology also at the University of California San Diego, said he was impressed by the study's use of 3D models. The advances in scientific visualization allow more accurate measurements and comparisons of specimens, said Levy, who was not involved in the research. The technology also offers archaeologists a fresh opportunity to review conclusions from objects excavated many years ago. Living in harmony Skhul Cave is one of three caves in the region that represent some of the oldest known intentional burials in the world, dating to more than 100,000 years ago, in the middle of the Paleolithic era. Multiple sets of remains were found at each site, and some are still being painstakingly excavated with tiny drills, which could provide more clues in the future. In ancient times, Israel was a land bridge and point of interaction between Neanderthals and Homo sapiens. Because Homo sapiens eventually replaced Neanderthals in the region and across the world, many people speculate that their interactions were violent and hostile, with Homo sapiens eventually responsible for the 'total elimination' of Neanderthals, Hershkovitz said. 'What Skhul is telling us is that Homo sapiens are not a vicious, aggressive creature, but one that managed to live in peace' with other groups, he said. 'Our aggressive behavior, which continues today in our long history, is a recent phenomenon that has cultural roots and not biological roots.'
